Brainstorm Cell Ownership
| BCLI Stock | USD 1.74 0.12 7.41% |
Shares in Circulation | First Issued 2002-06-30 | Previous Quarter 4.7 M | Current Value 5.3 M | Avarage Shares Outstanding 14.3 M | Quarterly Volatility 13.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Brainstorm |
Brainstorm Stock Ownership Analysis
About 14.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 3.45. Brainstorm Cell Ther had not issued any dividends in recent years. The entity had 1:15 split on the 1st of October 2024. Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. Brainstorm Cell operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 43 people. For more info on Brainstorm Cell Therapeutics please contact Chaim Lebovits at 201 488 0460 or go to https://www.brainstorm-cell.com.Besides selling stocks to institutional investors, Brainstorm Cell also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Brainstorm Cell's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Brainstorm Cell's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Brainstorm Cell Quarterly Liabilities And Stockholders Equity |
|
About 9.0% of Brainstorm Cell Therapeutics are currently held by insiders. Unlike Brainstorm Cell's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Brainstorm Cell's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Brainstorm Cell's insider trades
Brainstorm Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Brainstorm Cell is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Brainstorm Cell Therapeutics backward and forwards among themselves. Brainstorm Cell's institutional investor refers to the entity that pools money to purchase Brainstorm Cell's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Securities, Llc | 2024-06-30 | 102 K | Tower Research Capital Llc | 2024-06-30 | 86.6 K | Virtu Financial Llc | 2024-06-30 | 49.6 K | Group One Trading, Lp | 2024-06-30 | 46.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 37 K | Wells Fargo & Co | 2024-06-30 | 28.8 K | Creative Planning Inc | 2024-06-30 | 20.9 K | Janney Montgomery Scott Llc | 2024-06-30 | 20.5 K | Jane Street Group Llc | 2024-06-30 | 19.8 K | Armistice Capital, Llc | 2024-06-30 | 7.9 M | Vanguard Group Inc | 2024-06-30 | 1.5 M |
Brainstorm Cell Ther Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Brainstorm Cell insiders, such as employees or executives, is commonly permitted as long as it does not rely on Brainstorm Cell's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Brainstorm Cell insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Brainstorm Cell Outstanding Bonds
Brainstorm Cell issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Brainstorm Cell Ther uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Brainstorm bonds can be classified according to their maturity, which is the date when Brainstorm Cell Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Currently Active Assets on Macroaxis
When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Brainstorm Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brainstorm Cell. If investors know Brainstorm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brainstorm Cell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.45) | Return On Assets (1.78) | Return On Equity (11.22) |
The market value of Brainstorm Cell Ther is measured differently than its book value, which is the value of Brainstorm that is recorded on the company's balance sheet. Investors also form their own opinion of Brainstorm Cell's value that differs from its market value or its book value, called intrinsic value, which is Brainstorm Cell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brainstorm Cell's market value can be influenced by many factors that don't directly affect Brainstorm Cell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brainstorm Cell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Brainstorm Cell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brainstorm Cell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.